NRX Pharmaceuticals, Inc. - Common Stock NRXP 深 滬
已收盤 08-01 16:00:00 美东时间
2.59
-0.100
-3.72%
華盛通- 最 高2.6899
- 今 開2.66
- 成交量 12.47万股
- 最 低 2.56
- 昨 收 2.69
- 總市值 5051.38万
- 52周最高 6.01
- 市盈率 靜 --
- 換手率 0.64%
- 52周最低 1.10
- 委 比 61.79%
- 總股本 1950.34万
- 歷史最高 769.90
- 量 比 0.90
- 振 幅 4.83%
- 歷史最低 1.58
- 每 手 1
- 風險率 0.81%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多NRx Pharmaceuticals (NASDAQ: NRXP) Charts Dual-Path for NRX-100
Austin, Texas, United States, July 21st, 2025, FinanceWire NRx Pharmaceuticals ...
07-22 01:00
美股大行评级 | 潜在涨幅378.93%！aTyr Pharma获富国银行升目标价至25美元，维持"超配"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1143101010774646784.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• 富国银行：维持aTyr Pharma(ATYR)"超配"评级，目标价从17美元升至25美元</p> <p>• 摩根大通：维持Array Technologies(ARRY)"超配"评级，目标价从12美元升至13美元</p>
06-21 08:35
D. Boral Capital Maintains Buy on NRX Pharmaceuticals, Maintains $31 Price Target
D. Boral Capital analyst Jason Kolbert maintains NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and maintains $31 price target.
06-20 23:42
NRx Pharmaceuticals And HOPE Therapeutics Announce Strategic Investor Relations Partnership With Life Sciences Advisory Firm Astr Partners
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) ("NRx Pharmaceuticals", "NRx" or the "Company"), a clinical-stage biopharmaceutical company, and HOPE Therapeutics, Inc., ("HOPE," or the "Company"), a multi-site clinical care
06-16 20:15
Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nurix Therapeutics announced on June 10, 2025, that it granted inducement awards to 17 new employees under its 2024 Equity Inducement Plan. The awards include stock options for 97,400 shares and restricted stock units (RSUs) for 66,750 shares. Stock options vest over four years, with 1/4 vesting after the first year and 1/48 each month thereafter. RSUs vest with 1/4 after one year and 1/16 quarterly thereafter. The options have a 10-year term wit...
06-13 20:01
NRX Pharmaceuticals Submits FDA Application for NRX-100
An announcement from NRX Pharmaceuticals ( ($NRXP) ) is now available. On June ...
06-10 00:47
NRx Pharmaceuticals Announces Transmission Of Its Abbreviated New Drug Application To The U.S FDA For NRX-100, Its Preservative-Free IV Ketamine Formulation For Use In All Existing Approved Indications
Ketamine faces a current US drug shortage not expected to abate in the near future1Current ketamine market estimated at $750 million and projected to reach $3.35 billion globally in 2034.2 NRx anticipates
06-05 20:10
美股大行评级 | 潜在涨幅2840.31%！Mersana Therapeutics获Truist Securities升目标价至10美元，维持"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1130419824951111681.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Truist Securities：维持Mersana Therapeutics(MRSN)"买入"评级，目标价从9美元升至10美元</p> <p>• Guggenheim：维持Cabaletta Bio(CABA)"买入
05-17 08:44
D. Boral Capital Maintains Buy on NRX Pharmaceuticals, Maintains $31 Price Target
D. Boral Capital analyst Jason Kolbert maintains NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and maintains $31 price target.
05-17 04:01
